Presentation is loading. Please wait.

Presentation is loading. Please wait.

Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)

Published bySamuel Potter Modified over 4 years ago

Similar presentations

Presentation on theme: "Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)"— Presentation transcript:

1 Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B).
Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B). A, Best percent change from baseline in sum of longest diameter in patients with target lesions (n = 26) at screening B, PFS in all patients and first-line patients (patients who were treatment-naïve or >190 days since previous therapy for localized gastric/GEJ adenocarcinoma). SLD, sum of longest diameter; 1L, first-line patients. Manish A. Shah et al. Clin Cancer Res 2018;24: ©2018 by American Association for Cancer Research

Download ppt "Efficacy summary for patients with gastric/GEJ adenocarcinoma (part B)"

Similar presentations

Dose-escalation patient response.

Dose-escalation patient response.
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.

Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight change. Key clinical efficacy outcomes for (A) hemoglobin A1c (HbA1c), (B) weight.
Successful tissue collection in patients with relapse of EGFR-positive adenocarcinoma after EGFR-TKI treatment. Successful tissue collection in patients.

Successful tissue collection in patients with relapse of EGFR-positive adenocarcinoma after EGFR-TKI treatment. Successful tissue collection in patients.
Treatment of Locally Advanced Pancreatic Cancer

Treatment of Locally Advanced Pancreatic Cancer
Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.

Waterfall plot of the best per cent change from baseline in SLD of target lesions in 33 patients. Waterfall plot of the best per cent change from baseline.
Waterfall plots of the best per cent change from baseline in sum of longest diameters (SLD) for target lesions. Waterfall plots of the best per cent change.

Waterfall plots of the best per cent change from baseline in sum of longest diameters (SLD) for target lesions. Waterfall plots of the best per cent change.
Rapid response to F16-IL2 and LDAC in disseminated extramedullary AML

Rapid response to F16-IL2 and LDAC in disseminated extramedullary AML
Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.

Serial measurements of serum glucose, anion gap, serum carbon dioxide, and serum triglycerides throughout the patient's hospital stay. Serial measurements.
Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.
The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.

The contributions of anti-Ad antibody and T-cell responses to viral clearance in tumor and antitumor efficacy of Ad5 therapy. The contributions of anti-Ad.
A and B, Computed tomography (CT) of the chest prior to cabozantinib therapy demonstrated a dominant mass in the left upper lobe (B, black arrow), measuring.

A and B, Computed tomography (CT) of the chest prior to cabozantinib therapy demonstrated a dominant mass in the left upper lobe (B, black arrow), measuring.
Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.

Association between RB pathway alterations and poor prognosis in early-stage lung adenocarcinoma patients. Association between RB pathway alterations and.
Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.

Mean changes (standard error) from baseline in A1C (A and B) and body weight (C and D) for patients with type 1 (A and C) or type 2 (B and D) diabetes.
Effect of nicotinamide and carbogen on 5-FU uptake (measured as SUV3

Effect of nicotinamide and carbogen on 5-FU uptake (measured as SUV3
Vascular staining in CWR22R xenograft tumors.

Vascular staining in CWR22R xenograft tumors.
Time to onset of hypothyroidism after first treatment with immune checkpoint inhibitors in the combination therapy and monotherapy groups. Time to onset.

Time to onset of hypothyroidism after first treatment with immune checkpoint inhibitors in the combination therapy and monotherapy groups. Time to onset.
Study overview. Study overview. A, Schematic illustrating clinical trial design and the nature and number of tissue specimens available for downstream.

Study overview. Study overview. A, Schematic illustrating clinical trial design and the nature and number of tissue specimens available for downstream.
Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical.

Personalized, 16-plex assays accurately detect ctDNA ahead of clinical relapse. Personalized, 16-plex assays accurately detect ctDNA ahead of clinical.
The antitumor and antimetastatic properties of PF-03084014 in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF-03084014 in the.

The antitumor and antimetastatic properties of PF in the MX1 orthotopic model. The antitumor and antimetastatic properties of PF in the.

Similar presentations

Ads by Google